On August 13, 2026, a three-judge panel of the U.S. Court of Appeals for the Third Circuit unanimously affirmed summary judgment in favor of Defendant Ranbaxy Pharmaceuticals, Inc. (“Ranbaxy”) in In re Lipitor Antitrust Litigation, agreeing with Judge Peter G. Sheridan of the U.S. District Court for the District of New Jersey that the plaintiffs lacked antitrust standing because they failed to demonstrate that, but for the challenged agreement, they “would have” been—as opposed to merely “could have” been—in a better position, reaffirming the Third Circuit’s prior decision in In re Wellbutrin XL Antitrust Litigation.1
Lipitor is a brand-name cholesterol medication that was launched by Pfizer, Inc. (“Pfizer”) in 1997.2 Pfizer claimed that multiple patents covered Lipitor.3
In 2002, Ranbaxy filed an Abbreviated New Drug Application (“ANDA”), seeking FDA approval to market a generic version of Lipitor.4 Ranbaxy’s ANDA qualified for first-filer exclusivity, meaning Ranbaxy would have generic market exclusivity for 180 days.5 Pfizer thereafter sued Ranbaxy for patent infringement.6
In June 2008, Pfizer and Ranbaxy settled their litigations,7 with Pfizer granting Ranbaxy a license permitting Ranbaxy to launch its generic of Lipitor on November 30, 2011—“approximately five years prior to the expiration of Pfizer’s latest-expiring Lipitor patent.”8
After resolving several issues related to Ranbaxy’s Lipitor ANDA, the FDA approved the ANDA on November 30, 2011, clearing Ranbaxy to market its generic.9
In November 2011, private plaintiffs filed putative class actions against Pfizer and Ranbaxy.10 The plaintiffs claimed that the Lipitor patent settlement violated state and federal antitrust laws because it contained an allegedly illegal reverse payment from Pfizer to Ranbaxy to delay Ranbaxy’s launch of generic Lipitor,11 and caused the plaintiffs to pay for the more-expensive branded Lipitor for a prolonged period of time.12
In March 2023, Pfizer and Ranbaxy moved for summary judgment, asserting that the plaintiffs could not prove that the challenged agreement caused any antitrust injury, such that the plaintiffs lacked antitrust standing.13 Specifically, the defendants argued that the plaintiffs lacked evidence that the FDA would have approved Ranbaxy’s ANDA even a day earlier had Pfizer provided Ranbaxy a license to market its generic earlier.14 Before the district court ruled on this motion, Pfizer settled out of the case, agreeing to pay a combined total of $128 million to the putative direct-purchaser and end-payor classes.15
On June 6, 2024, the district court granted Ranbaxy’s motion for summary judgment.16 Focusing on the causation issue, the district court agreed with defendants that the plaintiffs failed to create a genuine issue of material fact because their “evidence showing that FDA ‘may have been able’ to approve Ranbaxy’s Lipitor ANDA” before November 30, 2011 did not meet the governing “would have” standard under Third Circuit law.17 Plaintiffs appealed.
On August 13, 2026, a panel of the Third Circuit affirmed the district court’s order.18 The panel stated that “[i]n a reverse payment case like this one, Plaintiffs must show that ‘the harm they say they experienced—increased drug prices for [Lipitor]—was caused by the settlement they are complaining about.’”19 Therefore, the plaintiffs were required to show that, absent the challenged agreement, “a generic version of Lipitor would have entered the market with FDA approval” before November 30, 2011, “which would have lowered prices.”20 The panel asserted that, to survive summary judgment, it was not enough for the plaintiffs to show that the FDA “may have” approved a generic version of a drug or that the generic version “may have” entered the market sooner; instead, the plaintiffs were required to demonstrate these things “would have” happened.21
The panel acknowledged the plaintiffs’ evidence showing that “the FDA would have endeavored to approve the entry of a generic Lipitor product before November 30, 2011,” but ultimately found that “in the but-for world, Plaintiffs have not shown that the FDA would have succeeded in doing so.”22 Accordingly, the panel affirmed, holding that the district court did not err in granting summary judgment to Ranbaxy because the plaintiffs lacked antitrust standing.23
The Third Circuit’s decision in Lipitor reaffirms the requirement that private antitrust plaintiffs must establish antitrust injury and causation as elements of their claims. In particular, where intervening factors bear on whether the challenged conduct actually caused the alleged injury, those factors may break the causal chain and preclude a finding of antitrust injury. Here, the court held that plaintiffs were required to show that, absent the challenged agreement, FDA approval of generic Lipitor would have occurred earlier—not merely that earlier approval may have or could have occurred. Thus, the decision underscores that plaintiffs cannot establish antitrust injury through speculative “but for” scenarios that do not demonstrate the requisite causal connection between the challenged conduct and the alleged harm.
Defendants, particularly those litigating in the Third Circuit, should consider as part of their early case-development strategy what evidence plaintiffs will need to meet the “would have” standard to establish that the alleged conduct caused the claimed injury and whether intervening factors undermine that causal showing. Careful attention to the causal-chain analysis and the antitrust-injury requirement can provide a sound basis for dismissal or summary judgment where plaintiffs cannot bridge the gap between alleged conduct and proven harm.
